A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni(Azienda Usl Toscana Centro), Ilenia Migliaccio(Hospital of Prato)
Cited by 170
Related Papers
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
|Cell|2011|276
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
|Clinical Cancer Research|2011|181
Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
|Cancer Research|2008|138
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
|npj Breast Cancer|2018|134
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
|Cancer Treatment Reviews|2023|54